Potassium binder lets heart patients get full drug benefits
NCT ID NCT05004363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a drug called Lokelma (SZC) can help people with both chronic kidney disease and heart failure safely reach higher doses of life-saving heart medications (RAAS inhibitors) without dangerous potassium spikes. 112 adults with stable kidney disease and heart failure took either Lokelma or a placebo while doctors gradually increased their heart medication doses. The goal was to see if Lokelma allowed more patients to reach the maximum recommended heart drug dose while keeping potassium levels safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACE INHIBITOR INDUCED HYPERKALAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St Georges, University of London
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could continuing a common heart drug before surgery save lives?
- Can a new graft keep dialysis access working longer?
- Can a common gout pill shield hearts in kidney disease?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes